
### [MONDO:0005357](http://purl.obolibrary.org/obo/MONDO_0005357)
**Label:** Creutzfeldt Jacob disease

**Subclasses:** [MONDO:0007403](http://purl.obolibrary.org/obo/MONDO_0007403) (inherited Creutzfeldt-Jakob disease), [MONDO:0018686](http://purl.obolibrary.org/obo/MONDO_0018686) (acquired Creutzfeldt-Jakob disease), [MONDO:0016079](http://purl.obolibrary.org/obo/MONDO_0016079) (sporadic Creutzfeldt-Jakob disease), [MONDO:0005409](http://purl.obolibrary.org/obo/MONDO_0005409) (variant Creutzfeld Jacob disease), [MONDO:0006518](http://purl.obolibrary.org/obo/MONDO_0006518) (sporadic Creutzfeld Jacob disease), 

**Mapped go classes:** [GO:0042613](http://purl.obolibrary.org/obo/GO_0042613) (MHC class II protein complex), [GO:0009897](http://purl.obolibrary.org/obo/GO_0009897) (external side of plasma membrane), [GO:0002381](http://purl.obolibrary.org/obo/GO_0002381) (immunoglobulin production involved in immunoglobulin mediated immune response), [GO:0005794](http://purl.obolibrary.org/obo/GO_0005794) (Golgi apparatus), [GO:0005771](http://purl.obolibrary.org/obo/GO_0005771) (multivesicular body), [GO:0004784](http://purl.obolibrary.org/obo/GO_0004784) (superoxide dismutase activity), [GO:0003674](http://purl.obolibrary.org/obo/GO_0003674) (molecular_function), [GO:0046635](http://purl.obolibrary.org/obo/GO_0046635) (positive regulation of alpha-beta T cell activation), [GO:0002344](http://purl.obolibrary.org/obo/GO_0002344) (B cell affinity maturation), [GO:0002455](http://purl.obolibrary.org/obo/GO_0002455) (humoral immune response mediated by circulating immunoglobulin), [GO:0030425](http://purl.obolibrary.org/obo/GO_0030425) (dendrite), [GO:0005769](http://purl.obolibrary.org/obo/GO_0005769) (early endosome), [GO:0006955](http://purl.obolibrary.org/obo/GO_0006955) (immune response), [GO:0002579](http://purl.obolibrary.org/obo/GO_0002579) (positive regulation of antigen processing and presentation), [GO:0005507](http://purl.obolibrary.org/obo/GO_0005507) (copper ion binding), [GO:0046982](http://purl.obolibrary.org/obo/GO_0046982) (protein heterodimerization activity), [GO:0005509](http://purl.obolibrary.org/obo/GO_0005509) (calcium ion binding), [GO:0048002](http://purl.obolibrary.org/obo/GO_0048002) (antigen processing and presentation of peptide antigen), [GO:1990405](http://purl.obolibrary.org/obo/GO_1990405) (protein antigen binding), [GO:0019882](http://purl.obolibrary.org/obo/GO_0019882) (antigen processing and presentation), [GO:0019886](http://purl.obolibrary.org/obo/GO_0019886) (antigen processing and presentation of exogenous peptide antigen via MHC class II), [GO:0015643](http://purl.obolibrary.org/obo/GO_0015643) (toxic substance binding), [GO:0042605](http://purl.obolibrary.org/obo/GO_0042605) (peptide antigen binding), [GO:0051260](http://purl.obolibrary.org/obo/GO_0051260) (protein homooligomerization), [GO:0008134](http://purl.obolibrary.org/obo/GO_0008134) (transcription factor binding), [GO:0002376](http://purl.obolibrary.org/obo/GO_0002376) (immune system process), [GO:0005886](http://purl.obolibrary.org/obo/GO_0005886) (plasma membrane), [GO:0005622](http://purl.obolibrary.org/obo/GO_0005622) (intracellular), [GO:0005544](http://purl.obolibrary.org/obo/GO_0005544) (calcium-dependent phospholipid binding), [GO:0009986](http://purl.obolibrary.org/obo/GO_0009986) (cell surface), [GO:0005515](http://purl.obolibrary.org/obo/GO_0005515) (protein binding), [GO:0031625](http://purl.obolibrary.org/obo/GO_0031625) (ubiquitin protein ligase binding), [GO:0002504](http://purl.obolibrary.org/obo/GO_0002504) (antigen processing and presentation of peptide or polysaccharide antigen via MHC class II), [GO:0042130](http://purl.obolibrary.org/obo/GO_0042130) (negative regulation of T cell proliferation), [GO:0016020](http://purl.obolibrary.org/obo/GO_0016020) (membrane), [GO:0016021](http://purl.obolibrary.org/obo/GO_0016021) (integral component of membrane), [GO:0002827](http://purl.obolibrary.org/obo/GO_0002827) (positive regulation of T-helper 1 type immune response), [GO:0071346](http://purl.obolibrary.org/obo/GO_0071346) (cellular response to interferon-gamma), [GO:0106003](http://purl.obolibrary.org/obo/GO_0106003) (amyloid-beta complex), 

**Class expressions from DL-Learner:**

- [GO:0003823](http://purl.obolibrary.org/obo/GO_0003823) (antigen binding) 55.56%
- [GO:1990405](http://purl.obolibrary.org/obo/GO_1990405) (protein antigen binding) 52.78%
- [GO:0106003](http://purl.obolibrary.org/obo/GO_0106003) (amyloid-beta complex) 52.78%
- [GO:0046982](http://purl.obolibrary.org/obo/GO_0046982) (protein heterodimerization activity) 52.78%
- [GO:0044389](http://purl.obolibrary.org/obo/GO_0044389) (ubiquitin-like protein ligase binding) 52.78%
- [GO:0042613](http://purl.obolibrary.org/obo/GO_0042613) (MHC class II protein complex) 52.78%
- [GO:0042605](http://purl.obolibrary.org/obo/GO_0042605) (peptide antigen binding) 52.78%
- [GO:0031625](http://purl.obolibrary.org/obo/GO_0031625) (ubiquitin protein ligase binding) 52.78%
- [GO:0019886](http://purl.obolibrary.org/obo/GO_0019886) (antigen processing and presentation of exogenous peptide antigen via MHC class II) 52.78%
- [GO:0016721](http://purl.obolibrary.org/obo/GO_0016721) (oxidoreductase activity, acting on superoxide radicals as acceptor) 52.78%
- [GO:0015643](http://purl.obolibrary.org/obo/GO_0015643) (toxic substance binding) 52.78%
- [GO:0009986](http://purl.obolibrary.org/obo/GO_0009986) (cell surface) 52.78%
- [GO:0005794](http://purl.obolibrary.org/obo/GO_0005794) (Golgi apparatus) 52.78%
- [GO:0005771](http://purl.obolibrary.org/obo/GO_0005771) (multivesicular body) 52.78%
- [GO:0005770](http://purl.obolibrary.org/obo/GO_0005770) (late endosome) 52.78%


